Findings from DEVOTE support clinical benefits of the high-dose regimen of nusinersen (50 mg and 28 mg) in both ...
TG Therapeutics is gearing up for a new clinical trial, dubbed ULTIMATE, to test Briumvi in children and adolescents with ...
Amgen's Uplizna receives European approval to treat generalized myasthenia gravis: Thousand Oaks, California Saturday, February 14, 2026, 11:00 Hrs [IST] Amgen announced the Europ ...
The phase 2b study is an open-label trial that will enroll 40 men with advanced prostate cancer who are appropriate candidates for ADT. Participants will receive an initial loading dose of teverelix ...
Amgen today announced the European Commission (EC) has approved UPLIZNA® (inebilizumab) as an add-on treatment to standard ...
The decision by the EC was supported by data from the Myasthenia Gravis Inebilizumab Trial.
Biogen is transitioning from a shrinking MS franchise to a portfolio anchored in rare disease and Alzheimer’s therapies, ...
Chugai presents positive data from Part C of phase I/II NXTAGE study of NXT007 in people switching from emicizumab without a washout period at EAHAD Congress: Tokyo Wednesday, Feb ...
FDA priority review seeks marstacimab label expansion to ≥6 years with inhibitors and ages 6–11 without inhibitors, addressing populations with limited efficacy from factor replacement and high unmet ...
Dublin Live on MSN
Cabra, Dalkey and Raheny among neighbourhoods facing week of 'noisy' night time rail works
The safety critical maintenance work can potentially be noisy and may impact people whose homes are located near the railways ...
1) the active drug substance Axitinib, which used to belong to Pfizer, is an FDA-approved, oral, potent VEGFR inhibitor. So ...
US biotech giant Amgen today announced the European Commission (EC) has approved Uplizna (inebilizumab) as an add-on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results